Publicacions en col·laboració amb investigadors/es de Hospital Universitario Virgen del Rocío (24)

2024

  1. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

    Clinical and Translational Oncology

  2. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  3. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 2, pp. 161-170

  4. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study

    Cancers, Vol. 13, Núm. 18

  2. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

    European Journal of Cancer, Vol. 145, pp. 158-167

2018

  1. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer

    Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329

  2. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: Exploratory analyses of the RAISE trial and validation in an electronic medical record data set

    ESMO Open, Vol. 3, Núm. 3

  3. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry

    European Journal of Surgical Oncology, Vol. 44, Núm. 8, pp. 1191-1198

2017

  1. Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

    Cancer Chemotherapy and Pharmacology, Vol. 80, Núm. 3, pp. 599-608

2016

  1. Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI

    Annals of Oncology, Vol. 27, pp. vi198

2015

  1. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: The phase II AVAXIRI study

    BMC Cancer, Vol. 15, Núm. 1

  2. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

    The Lancet Oncology, Vol. 16, Núm. 5, pp. 499-508

  3. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273

2014

  1. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 942-953

2012

  1. Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739

  2. Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

    Revista Espanola de Patologia